Suchergebnisse - "Martens, Anne"

PubPharm (16)

1

Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors

enthalten in: Leukemia | 2023

von Martens, A. | Kavazović, I. | Krapić, M. | +9

2

Serpin B9 controls tumor cell killing by CAR T cells

enthalten in: Journal for immunotherapy of cancer | 2023

von Kimman, T. | Slomp, A. | Martens, A. | +10

3

T-cell subset composition and functionality in patients with Waldenström's macroglobulinemia

enthalten in: Leukemia & lymphoma | 2022

von Amaador, K. | Martens, A. | de Boer, R. | +8

4

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas

enthalten in: Cancer research communications | 2022

von Martens, A. | Rietveld, J. | de Boer, R. | +12

5

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia

enthalten in: Blood advances | 2021

von Kater, A. | Slinger, E. | Cretenet, G. | +4

6

Correction : van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837

enthalten in: Cancers | 2021

von van Bruggen, J. | Martens, A. | Tonino, S. | +1

ErratumFor: Cancers (Basel). 2020 Dec 18;12(12):. - PMID 33353234

7

Human CXCR5+ PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

enthalten in: European journal of immunology | 2021

von Hofland, T. | Martens, A. | van Bruggen, J. | +9

8

Human CXCR5+ PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

enthalten in: European Journal of Immunology | 2021

von Hofland, T. | Martens, A. | Bruggen, J. | +9

9

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

enthalten in: Cancers | 2020

von van Bruggen, J. | Martens, A. | Tonino, S. | +1

ErratumIn: Cancers (Basel). 2021 Sep 22;13(19):. - PMID 34638518

10

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

enthalten in: Journal for immunotherapy of cancer | 2020

von Martens, A. | Janssen, S. | Derks, I. | +7

ErratumIn: J Immunother Cancer. 2021 Aug;9(8):1. - PMID 34344798